# EDGAR Filing Document

**Accession Number:** 0000921114
**File Stem:** 0001104659-25-077650
**Filing Date:** 2025-8
**Character Count:** 33206
**Document Hash:** 543c5b3f173b006b9f6a3e5ffea3b104
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-077650.hdr.sgml**: 20250813

**ACCESSION NUMBER**: 0001104659-25-077650

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20250813

**DATE AS OF CHANGE**: 20250813

**EFFECTIVENESS DATE**: 20250813

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Armata Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0000921114
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 911549568
- **STATE OF INCORPORATION:** WA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289588
- **FILM NUMBER:** 251212922

**BUSINESS ADDRESS:**
- **STREET 1:** 5005 MCCONNELL AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90066
- **BUSINESS PHONE:** 310-665-2928

**MAIL ADDRESS:**
- **STREET 1:** 5005 MCCONNELL AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90066

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AmpliPhi Biosciences Corp
- **DATE OF NAME CHANGE:** 20130222

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TARGETED GENETICS CORP /WA/
- **DATE OF NAME CHANGE:** 19940331

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**ARMATA PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Washington** | **91-1549568** |
| (State or other jurisdiction of<br> incorporation or organization)  | (I.R.S. Employer<br> Identification No.)  |

---

**5005 McConnell Avenue**

**Los Angeles, CA 90066**

(Address of Principal Executive Offices) (Zip Code)

**Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan**

**Armata Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan**

(Full titles of the plans)

**Armata Pharmaceuticals, Inc.**

**5005 McConnell Avenue**

**Los Angeles, CA 90066**

**(Name and address of agent for service)**

**(310) 655-2928**

(Telephone number, including area code, of agent for service)

***Copies to:***

---

| | |
|:---|:---|
| **Deborah L. Birx**<br> **Armata Pharmaceuticals, Inc.**<br> **5005 McConnell Avenue**<br> **Los Angeles, CA 90066**<br> **(310) 655-2928** | **Jared Fertman**<br> **Willkie Farr & Gallagher LLP**<br> **787 Seventh Avenue**<br> **New York, New York 10019-6099**<br> **(212) 728-8000** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻ Accelerated filer ◻ <br> Non-accelerated filer ⌧ Smaller reporting company ⌧ <br> Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE<br> REGISTRATION OF ADDITIONAL SHARES<br> PURSUANT TO GENERAL INSTRUCTION E**

Pursuant to General Instruction E to Form S-8, this Registration Statement on Form S-8 (this "<u>Registration Statement</u>") is filed by Armata Pharmaceuticals, Inc. (the "<u>Registrant</u>") to register an additional 1,811,295 shares of the Registrant's common stock, par value $0.01 per share ("<u>Common Stock</u>"), issuable under the Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan (the "<u>Armata 2016 Plan</u>") or the Armata Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan (the "<u>Armata 2016 ESPP</u>"). Such shares consist of the following:

&nbsp;&nbsp;&nbsp;&nbsp;· (i) 1,809,153
 shares of Common Stock that were automatically added to the shares authorized for issuance
 under the Armata 2016 Plan on January 1, 2025, pursuant to an "evergreen"
 provision contained in the Armata 2016 Plan. Pursuant to such "evergreen" provision,
 on January 1st of each calendar year, from January 1, 2017 through and including
 January 1, 2026, the number of shares authorized for issuance under the Armata 2016
 Plan is automatically increased by: (a) a number equal to 5% of the total number of
 shares of the Registrant's capital stock outstanding on December 31st of the preceding
 calendar year, or (b) a lesser number of shares determined by the Registrant's
 board of directors (the " <u>Board</u> "); and

&nbsp;&nbsp;&nbsp;&nbsp;· (ii) 2,142
 shares of Common Stock that were automatically added to the shares authorized for issuance
 under the Armata 2016 ESPP on January 1, 2025, pursuant to an "evergreen"
 provision contained in the Armata 2016 ESPP. Pursuant to such provision, on January 1st
 of each calendar year, from January 1, 2017 through and including January 1, 2026,
 the number of shares authorized for issuance under the Armata 2016 ESPP is automatically
 increased by a number equal to the least of: (a) 1% of the total number of shares of
 the Registrant's capital stock outstanding on December 31st of the preceding calendar
 year; (b) 2,142 shares; or (c) a number determined by the Board that is less than
 (a) and (b).

This Registration Statement hereby incorporates by reference the contents of the Registrant's registration statement on Form S-8 filed with the Commission on [January 23, 2024 (File No. 333-276657)](https://www.sec.gov/Archives/edgar/data/921114/000110465924005889/tm243762d1_s8.htm), [November 15, 2023 (File No. 333-275580)](https://www.sec.gov/Archives/edgar/data/921114/000110465923118799/tm2330738d1_s8.htm), [June 22, 2016 (File No. 333-212183)](https://www.sec.gov/Archives/edgar/data/921114/000114420416109313/v442756_s8.htm), [May 1, 2017 (File No. 333-217563)](https://www.sec.gov/Archives/edgar/data/921114/000114420417023433/v465550_s-8.htm), [November 14, 2017 (File No. 333-221564)](https://www.sec.gov/Archives/edgar/data/921114/000114420417059121/tv479430_s-8.htm), [March 28, 2018 (File No. 333-223987)](https://www.sec.gov/Archives/edgar/data/921114/000114420418017547/tv489683_s8.htm), and [June 10, 2019 (File No. 333-232058)](https://www.sec.gov/Archives/edgar/data/921114/000114420419030481/tv523249_s-8.htm), respectively (the "<u>Prior Registration Statements</u>"), in each case, to the extent not superseded hereby. The additional shares of Common Stock being registered by this Registration Statement are of the same class as those securities registered on the Prior Registration Statements.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

All information required by Part I to be contained in the prospectus is omitted from this Registration Statement in accordance with Section 428 of the Securities Act of 1933, as amended (the "<u>Securities Act</u>") and the instructions to Form S-8 and instead will be delivered, pursuant to Rule 428 under the Securities Act, to each participant in the Armata 2016 Plan and the Armata 2016 ESPP, as applicable.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.** **Incorporation of Documents By Reference**

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plan are effective. Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

The following documents, which we have filed with the Securities and Exchange Commission (the "<u>Commission</u>"), are incorporated by reference in this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;· [The Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 20, 2025;](https://www.sec.gov/ix?doc=/Archives/edgar/data/921114/000155837025003406/armp-20241231x10k.htm)

&nbsp;&nbsp;&nbsp;&nbsp;· The
 Registrant's Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31,
 2025 and June 30, 2025 filed with the Commission on [May 14, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/921114/000155837025007765/armp-20250331x10q.htm) and [August 12, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/921114/000155837025011235/armp-20250630x10q.htm) ;

&nbsp;&nbsp;&nbsp;&nbsp;· [The Registrant's Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 28, 2025 (as amended and supplemented);](https://www.sec.gov/ix?doc=/Archives/edgar/data/921114/000110465925040273/tm252577-4_def14a.htm)

&nbsp;&nbsp;&nbsp;&nbsp;· The
 Registrant's Current Reports on Form 8-K, filed with the Commission on [March 12, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/921114/000110465925023015/tm258929d1_8k.htm) , [April 2, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/921114/000110465925031127/tm2511032d1_8k.htm) , [May 1, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/921114/000110465925043017/tm2513778d1_8k.htm) , [June 13, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/921114/000110465925059346/tm2517977d1_8k.htm) and [August 12, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/921114/000155837025011227/armp-20250811x8k.htm) (only with respect to information filed under items 1.01, 2.03 and 9.01); and

&nbsp;&nbsp;&nbsp;&nbsp;· The
 description of our common stock contained in our registration statement on [Form 8-A, filed with the Commission on August 18, 2015](https://www.sec.gov/Archives/edgar/data/921114/000114420415050355/v418421_8a12b.htm) , including all amendments and reports
 filed for the purpose of updating such description.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment that indicates that all shares of common stock offered hereby have been sold or which deregisters all shares of common stock then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents; *provided*, *however*, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this registration statement.

Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this registration statement.

**Item 8.** **Exhibits.**

The following exhibits are filed herewith:

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | <br>**Exhibit Description** |
| [4.1](https://www.sec.gov/Archives/edgar/data/921114/000114420415066161/v421749_ex3-1.htm) | [Amended and Restated Articles of Incorporation of the Company, as amended (incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q, filed with the SEC on November 16, 2015).](https://www.sec.gov/Archives/edgar/data/921114/000114420415066161/v421749_ex3-1.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/921114/000114420417021763/v464998_ex3-1.htm) | [Articles of Amendment to Amended and Restated Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K, filed with the SEC on April 24), 2017.](https://www.sec.gov/Archives/edgar/data/921114/000114420417021763/v464998_ex3-1.htm) |
| [4.3](https://www.sec.gov/Archives/edgar/data/921114/000114420418058340/tv505699_ex3-2.htm) | [Statement of Correction to Articles of Amendment to Amended and Restated Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.2 to the Company's Quarterly Report on Form 10-Q, filed on November 8, 2018).](https://www.sec.gov/Archives/edgar/data/921114/000114420418058340/tv505699_ex3-2.htm) |
| [4.4](https://www.sec.gov/Archives/edgar/data/921114/000114420418065017/tv509361_ex3-1.htm) | [Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on December 18, 2018).](https://www.sec.gov/Archives/edgar/data/921114/000114420418065017/tv509361_ex3-1.htm) |
| [4.5](https://www.sec.gov/Archives/edgar/data/921114/000114420419025292/tv521048_ex3-1.htm) | [Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on May 10, 2019).](https://www.sec.gov/Archives/edgar/data/921114/000114420419025292/tv521048_ex3-1.htm) |
| [4.6](https://www.sec.gov/Archives/edgar/data/921114/000110465919071854/tm1924941d1_ex3-1.htm) | [Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on December 11, 2019).](https://www.sec.gov/Archives/edgar/data/921114/000110465919071854/tm1924941d1_ex3-1.htm) |
| [4.7](https://www.sec.gov/Archives/edgar/data/921114/000110465920040578/tm2014179d1_ex3-1.htm) | [Articles of Amendment to Articles of Incorporation of the Company (effective March 26, 2020) (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, filed with the SEC on March 30, 2020).](https://www.sec.gov/Archives/edgar/data/921114/000110465920040578/tm2014179d1_ex3-1.htm) |
| [4.8](https://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex35124c484.htm) | [Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.5 to the Company's Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).](https://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex35124c484.htm) |
| [4.9](https://www.sec.gov/Archives/edgar/data/921114/000110465919071854/tm1924941d1_ex3-2.htm) | [Amendment to Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K, filed with the SEC on December 11, 2019).](https://www.sec.gov/Archives/edgar/data/921114/000110465919071854/tm1924941d1_ex3-2.htm) |
| [4.10](https://www.sec.gov/Archives/edgar/data/921114/000110465920025375/tm2010968d1_ex3-1.htm) | [Amendment to Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, filed with the SEC on February 26, 2020).](https://www.sec.gov/Archives/edgar/data/921114/000110465920025375/tm2010968d1_ex3-1.htm) |
| [5.1](tm2523056d1_ex5-1.htm) | [Opinion of Counsel](tm2523056d1_ex5-1.htm) |
| [23.1](tm2523056d1_ex23-1.htm) | [Consent of Independent Registered Public Accounting Firm](tm2523056d1_ex23-1.htm) |
| [23.2](tm2523056d1_ex5-1.htm) | [Consent of Counsel (included in Exhibit 5.1 to this Registration Stated and filed herewith)](tm2523056d1_ex5-1.htm) |
| [24.1](#a_001) | [Power of Attorney (included on the signature pages of this Registration Statement)](#a_001) |
| [99.1](http://www.sec.gov/Archives/edgar/data/921114/000114420419030481/tv523249_ex99-1.htm) | [Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan, as amended incorporated by reference to Exhibit 99.1 to the registrant's Registration Statement on Form S-8, filed with the SEC on June 10, 2019).](http://www.sec.gov/Archives/edgar/data/921114/000114420419030481/tv523249_ex99-1.htm) |
| [99.2](http://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex1010ab7df.htm) | [Armata Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.10 to the Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).](http://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex1010ab7df.htm) |
| [107](tm2523056d1_ex-filingfees.htm) | [Filing Fee Table](tm2523056d1_ex-filingfees.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California on August 13, 2025.

---

| | |
|:---|:---|
| **Armata Pharmaceuticals, Inc.** | **Armata Pharmaceuticals, Inc.** |
| By: | /s/ Deborah L. Birx |
|  | Deborah L. Birx |
|  | Chief Executive Officer |

---

**POWER OF ATTORNEY**

**Know All Persons By These Presents**, that each person whose signature appears below constitutes and appoints each of Deborah L. Birx and David D. House as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **SIGNATURE** | **TITLE** | **DATE** |
| /s/ Deborah L. Birx | Chief Executive Officer and Director | August 13, 2025 |
| Deborah L. Birx, M.D. | *(Principal Executive Officer)* |  |
| /s/ David D. House | Senior Vice President, Finance | August 13, 2025 |
| David D. House | *(Principal Financial Officer)* |  |
| /s/ Robin C. Kramer | Chair of the Board of Directors | August 13, 2025 |
| Robin C. Kramer |  |  |
| /s/ Jules Haimovitz | Director | August 13, 2025 |
| Jules Haimovitz |  |  |
| /s/ Odysseas D. Kostas | Director | August 13, 2025 |
| Odysseas D. Kostas, M.D. |  |  |
| /s/ Joseph M. Patti | Director | August 13, 2025 |
| Joseph M. Patti, Ph.D. |  |  |
| /s/ Todd C. Peterson | Director | August 13, 2025 |
| Todd C. Peterson, Ph.D. |  |  |
| /s/ Sarah J. Schlesinger | Director | August 13, 2025 |
| Sarah J. Schlesinger, M.D. |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](tm2523056d1_ex5-1img01.jpg)

1301 Second Avenue, Suite 2800 <br> Seattle, Washington 98101-3808<br> Tel: 206.223.7000<br> Fax: 206.223.7107<br> www.ballardspahr.com

Armata Pharmaceuticals, Inc.

5005 McConnell Avenue

Los Angeles, California 90066

RE: <u>Armata Pharmaceuticals, Inc. - Registration Statement on Form S-8</u>

Ladies and Gentlemen:

We have acted as special counsel to Armata Pharmaceuticals, Inc., a Washington corporation (the "**Company**"), in connection with a Registration Statement on Form S-8 (the "**Registration Statement**") filed on the date hereof with the Securities and Exchange Commission (the "**Commission**") under the Securities Act of 1933, as amended (the "**Securities Act**"). The Registration Statement relates to the proposed offering of up to 1,811,295 shares ("**Shares**") of common stock, par value $0.01 per share ("**Common Stock**") of the Company, 1,809,153 of which are issuable pursuant to the Company's 2016 Equity Incentive Plan, as amended (the "**Equity Plan**"), and 2,142 of which are issuable pursuant to the Company's 2016 Employee Stock Purchase Plan, as amended (the "**ESPP**", and together with the Equity Plan, the "**Plans**" and each a "**Plan**").

In connection with this opinion, we have examined originals or copies, certified or otherwise identified to our satisfaction, of (i) the Registration Statement and all exhibits thereto, (ii) the Amended and Restated Articles of Incorporation, as amended, of the Company as currently in effect, (iii) the Amended and Restated Bylaws, as amended, of the Company as currently in effect, (iv) the Equity Plan, (v) the ESPP, (vi) resolutions adopted by the Board of Directors of the Company and such other corporate records, agreements, documents and other instruments, and (vii) such certificates or comparable documents of public officials and officers and representatives of the Company, and have made such inquiries of such officers and representatives and have considered such matters of law as we have deemed appropriate as the basis for the opinions hereinafter set forth. As to facts material to this opinion letter, we have relied upon certificates, statements or representations of public officials, of officers and representatives of the Company and of others, without any independent verification thereof.

In rendering this opinion, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as certified, photostatic or conformed copies, the authenticity of originals of all such latter documents, and the accuracy and completeness of all records, information and statements submitted to us by officers and representatives of the Company.

The opinion expressed below is based on the assumption that the Registration Statement has been filed by the Company with the Commission and will have become effective before any of the Shares are issued, and that persons acquiring the Shares will do so strictly in accordance with the terms of the applicable Plan and will receive a prospectus containing all the information required by Part I of the Registration Statement before acquiring such Shares. The opinion is also based on the assumption that the Shares will continue to be duly and validly authorized on the dates that the Shares are issued to participants pursuant to the terms of the applicable Plan and, upon the issuance of any of the Shares, the total number of shares of common stock of the Company issued and outstanding, after giving effect to such issuance of such Shares, will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under its Articles of Incorporation. We have also assumed that the Company's board of directors, or a duly authorized committee thereof, will have approved the issuance of each award under the applicable Plan prior to the issuance thereof and have assumed the receipt by the Company of the consideration for the Shares specified in the applicable Plan.

Armata Pharmaceuticals, Inc.

Based upon the foregoing, and subject to the qualifications, assumptions and limitations stated herein, we are of the opinion that (a) the Shares to be issued under the Plans are duly authorized and (b) the Shares, when issued pursuant to the Plans and any applicable award agreement in accordance with the terms and conditions thereof (including, where applicable, the payment of any exercise price, the satisfaction of any vesting or forfeiture restrictions, and the achievement of applicable performance goals), will be validly issued, fully paid and non-assessable.

Our opinion is limited to the laws of the Washington Business Corporation Act and the federal laws of the United States of America, each as in effect on the date hereof, and we express no opinion with respect to the laws of any other jurisdiction.

This opinion letter has been prepared for your use in connection with the Registration Statement. We assume no obligation to advise you of any changes in the foregoing subsequent to the effective date of the Registration Statement.

We hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

---

| |
|:---|
| Sincerely, |
| /s/ Ballard Spahr LLP |

---

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2016 Equity Incentive Plan and the 2016 Employee Stock Purchase Plan of Armata Pharmaceuticals, Inc. of our report dated March 20, 2025, with respect to the consolidated financial statements of Armata Pharmaceuticals, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Diego, California

August 13, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Armata Pharmaceuticals, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, par value $0.01 per share | Other | 1809153 | $2.50 | $4522882.50 | 0.0001531 | $692.45 |
| 2 | Equity | Common Stock, par value $0.01 per share | Other | 2142 | $2.50 | $5355.00 | 0.0001531 | $0.82 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $4528237.50  |  | $693.27  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $693.27  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> (1.a) The offering price per unit and in the aggregate are estimated in accordance with Rules 457(c) and 457(h) under the Securities Act of 1933, as amended (the "Securities Act") solely for the purpose of calculating the registration fee. (1.b) Pursuant to Rule 416(a) under the Securities Act, this Registration Statement shall also cover any additional shares of the registrant's Common Stock, par value $0.01 per share ("Common Stock") of Armata Pharmaceuticals, Inc. (the "Company") that become issuable under the Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan (the "Armata 2016 Plan") or the Armata Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan (the "Armata 2016 ESPP") by reason of any future stock dividend, stock split, recapitalization or other similar adjustments of the outstanding Common Stock. (1.c) Represents 1,809,153 shares of Common Stock that were automatically added to the shares authorized for issuance under the Armata 2016 Plan on January 1, 2025, pursuant to an "evergreen" provision contained in the Armata 2016 Plan. Pursuant to such "evergreen" provision, on January 1st of each calendar year, from January 1, 2017 through and including January 1, 2026, the number of shares authorized for issuance under the Armata 2016 Plan is automatically increased by: (a) a number equal to 5% of the total number of shares of the Company's capital stock outstanding on December 31st of the preceding calendar year, or (b) a lesser number of shares determined by the Company's board of directors (the "Board"). (1.d) Estimated solely for purposes of calculating the amount of the registration fee, pursuant to Rules 457(c) and 457(h) under the Securities Act, the proposed maximum aggregate offering price is the product obtained by multiplying (i) $2.50 (the average of the high and low prices of the Company's Common Stock on August 8, 2025, as reported on the NYSE American) by (ii) 1,811,295 (the number of shares of Common Stock issuable in connection with equity awards that may be granted in the future pursuant to the Armata 2016 Plan or the Armata 2016 ESPP). (1.e) The amount of registration fee is calculated only with respect to the additional shares of Common Stock registered on this Registration Statement. The existing securities issuable under the Armata 2016 Plan and Armata 2016 ESPP were registered, and the correlating registration fee paid, pursuant to the Registration Statements on Form S-8 filed on January 23, 2024 (File No. 333-276657), November 15, 2023 (File No. 333-275580), June 22, 2016 (File No. 333-212183), May 1, 2017 (File No. 333-217563), November 14, 2017 (File No. 333-221564), March 28, 2018 (File No. 333-223987), and June 10, 2019 (File No. 333-232058).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> See offering notes 1.a, 1.b, 1.c, 1.d, and 1.e (2.a) Represents 2,142 shares of Common Stock that were automatically added to the shares authorized for issuance under the Armata 2016 ESPP on January 1, 2025, pursuant to an "evergreen" provision contained in the Armata 2016 ESPP. Pursuant to such provision, on January 1st of each calendar year, from January 1, 2017 through and including January 1, 2026, the number of shares authorized for issuance under the Armata 2016 ESPP is automatically increased by a number equal to the least of: (a) 1% of the total number of shares of the Company's capital stock outstanding on December 31st of the preceding calendar year; (b) 2,142 shares; or (c) a number determined by the Board that is less than (a) and (b).

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---